Format

Send to

Choose Destination
Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31.

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.

Author information

1
Department of Hematology, University Hospital of Liege, Belgium jo.caers@chu.ulg.ac.be.
2
Laboratory of Hematology, GIGA-I3, University of Liège, Belgium.
3
Department of Hematology, Hopital Saint Antoine, Paris, France.
4
Department of Internal Medicine II, University Hospital of Wuerzburg, Germany.
5
Department of Hematology, National University of Ireland Galway, Ireland.
6
Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
7
Department of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
8
Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany.
9
Department of Hematology-Oncology, University Hospital Città della Salute e della Scienza, Torino, Italy.
10
Unit for Genomics in Myeloma, Institut Universitaire du Cancer - Oncopole, Toulouse, France.
11
Department of Hematology, University Hospital of Liege, Belgium.
12
Wilhelminen Cancer Research Institute, Vienna, Austria.
13
Department of Oncology and Hematology, Cantonal Hospital St. Gallen, Switzerland.
14
School of Medicine, National and Kapodistrian University of Athens, Greece.
15
Division of Stem Cell Transplantation and Immunotherapy, University of Kiel, Germany.
16
Seragnoli 'Institute of Hematology, Bologna University School of Medicine, Italy.
17
Department of Hematology, Rheumatology and Oncology, University Hospital Heidelberg, Germany.
18
National Center for Tumor Diseases, Heidelberg Medical University, Germany.
19
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
20
Department of Hematology, University Hospital Leuven, Belgium.
21
Centre for Haematology, Hammersmith Hospital, Imperial College London, UK.

Abstract

The diagnosis of multiple myeloma can be challenging, even for experienced physicians, and requires close collaboration between numerous disciplines (orthopedics, radiology, nuclear medicine, radiation therapy, hematology and oncology) before the final diagnosis of myeloma is made. The definition of multiple myeloma is based on the presence of clinical, biochemical, histopathological, and radiological markers of disease. Specific tests are needed both at presentation and during follow-up in order to reach the correct diagnosis and characterize the disease precisely. These tests can also serve prognostic purposes and are useful for follow-up of myeloma patients. Molecular analyses remain pivotal for defining high-risk myeloma and are used in updated patient stratifications, while minimal residual disease assessment via flow cytometry, molecular techniques and radiological approaches provides additional prognostic information on patients' long-term outcome. This pivotal information will guide our future treatment decisions in forthcoming clinical trials. The European Myeloma Network group updated their guidelines on different diagnostic recommendations, which should be of value to enable appropriate use of the recommendations both at diagnosis and during follow-up.

PMID:
30171031
DOI:
10.3324/haematol.2018.189159
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center